Three-gene molecular diagnostic model for thyroid cancer

Thyroid

Volumn 22, Issue 3, 2012, Pages 275-284

  Prasad, Nijaguna B ^a   Kowalski, Jeanne ^a   Tsai, Hua Ling ^a   Talbot, Kristin ^a   Somervell, Helina ^a   Kouniavsky, Guennadi ^a   Wang, Yongchun ^a   Dackiw, Alan P B ^a   Westra, William H ^a   Clark, Douglas P ^a   Libutti, Steven K ^b   Umbricht, Christopher B ^a   Zeiger, Martha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASPIRATION BIOPSY; GENE; HMGA2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; MRC2 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SFN GENE; THYROID CANCER; THYROID NODULE; THYROID TUMOR;

14-3-3 PROTEINS; BIOPSY, FINE-NEEDLE; CASE-CONTROL STUDIES; EXONUCLEASES; GENETIC MARKERS; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MANNOSE-BINDING LECTINS; MEMBRANE GLYCOPROTEINS; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863230507     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0169     Document Type: Article

References (47)

1. Mazzaferri EL 1993 Management of a solitary thyroid nodule. N Engl J Med 328:553-559.
2. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E, Alexander EK 2006 Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 91:3411-3417.
3. Izquierdo R, Arekat MR, Knudson PE, Kartun KF, Khurana K, Kort K, Numann PJ 2006 Comparison of palpationguided versus ultrasound-guided fine-needle aspiration biopsies of thyroid nodules in an outpatient endocrinology practice. Endocr Pract 12:609-614.
4. Gharib H, Papini E 2007 Thyroid nodules: Clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 36:707-735, vi.
5. Banks ND, Kowalski J, Tsai HL, Somervell H, Tufano R, Dackiw AP, Marohn MR, Clark DP, Umbricht CB, Zeiger MA 2008 A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid 18:933-941.
6. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 36:425-437.
7. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nose V, Marqusee E, Larsen PR, Alexander EK 2007 Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111:508-516.
8. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092-2098.
9. Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A 2008 The National Cancer Institute thyroid fine needle aspiration state of the science conference: A summation. Cytojournal 5:6.
10. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049.
11. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey TJ 3rd 2003 Classification of follicular thyroid tumors by molecular signature: Results of gene profiling. Clin Cancer Res 9:1792-1800.
12. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ 2004 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242.
13. Jarzab B, Wiench M, Fujarewicz K, Simek K, JarzabM, Oczko-Wojciechowska M,Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A 2005 Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Res 65:1587-1597.
14. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903.
15. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT, Fahey TJ 3rd 2006 Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8:490-498; quiz 528.
16. Yukinawa N, Oba S, Kato K, Taniguchi K, Iwao-Koizumi K, Tamaki Y, Noguchi S, Ishii S 2006 A multi-class predictor based on a probabilistic model: Application to gene expression profiling-based diagnosis of thyroid tumors. BMC Genomics 7:190.
17. Fujarewicz K, Jarzab M, Eszlinger M, Krohn K, Paschke R, Oczko-Wojciechowska M, Wiench M, Kukulska A, Jarzab B, Swierniak A 2007 A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: Gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 14:809-826.
18. Nikolova DN, Zembutsu H, Sechanov T, Vidinov K, Kee LS, Ivanova R, Becheva E, Kocova M, Toncheva D, Nakamura Y 2008 Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep 20:105-121.
19. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA 2008 Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 14:3327-3337.
20. Fedor HL, De Marzo AM 2005 Practical methods for tissue microarray construction. Methods Mol Med 103:89-101.
21. DeLong ER, DeLong DM, Clarke-Pearson DL 1988 Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845.
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
23. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982.
24. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326.
25. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Rigl CT, Friedman L, Wang CC, Lanman RB, Zeiger M, Kebebew E, Rosai J, Fellegara G, LiVolsi VA, Kennedy GC 2010 Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 95:5296-5304.
26. Hucz J, Kowalska M, Jarzab M, Wiench M 2006 [Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer.]. Endokrynol Pol 57:18-25.
27. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Nakamura Y, Kakudo K, Kuma K, Miyauchi A 2005 Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol Res Pract 201:545-549.
28. Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A 2008 HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 44:1015-1021.
29. de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF 2008 Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: Comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98:818-823.
30. Murphy KM, Chen F, Clark DP 2008 Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol 39:420-426.
31. Lal G, Padmanabha L, Provenzano M, Fitzgerald M,Weydert J, Domann FE 2008 Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation. Cancer Lett 267:165-174.
32. Xu MR, Chen Y, Zhou SR, Chi MM, Chen SL, Liu LY 2009 [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi 31:356-360.
33. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
34. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90:2512-2521.
35. Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E 2008 Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer 113:930-935.
36. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ 2006 Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res 12:3311-3318.
37. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM 2009 HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 22:43-49.
38. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P, Liu J 2010 HMGA2: A potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 34:18-26.
39. Madsen DH, Engelholm LH, Ingvarsen S, Hillig T, Wagenaar-Miller RA, Kjoller L, Gardsvoll H, Hoyer-Hansen G, Holmbeck K, Bugge TH, Behrendt N 2007 Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J Biol Chem 282:27037-27045.
40. Kogianni G, Walker MM, Waxman J, Sturge J 2009 Endo180 expression with cofunctional partners MT1-MMP and uPARuPA is correlated with prostate cancer progression. Eur J Cancer 45:685-693.
41. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S 2005 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatinplus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 23:9105-9112.
42. Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM, Holm R 2008 The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer 8:308.
43. Neupane D, Korc M 2008 14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res 14:7614-7623.
44. Nakayama H, Sano T, Motegi A, Oyama T, Nakajima T 2005 Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int 55:707-715.
45. Sano T, Shimooka H, Weixa P, Segawa A, Jian Z, Motegi A, Nakayama H, Oyama T, Nakajima T 2004 Immunohistochemical expression of 14-3-3 sigma protein in various histological subtypes of uterine cervical cancers. Pathol Int 54:743-750.
46. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R, Amberger A 2005 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11:3274-3279.
47. Li DJ, Deng G, Xiao ZQ, Yao HX, Li C, Peng F, Li MY, Zhang PF, Chen YH, Chen ZC 2009 Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett 279:65-73.